Merck's Keytruda boosts response in hard-to-treat lung cancer

(Reuters) - The combination of Merck&Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

AbstractOver the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develop resistance to these targeted therapies. Recently, immunotherapies such as immune checkpoint inhibitors have revolutionized the treatment paradigm for many types of malignancies. Immune checkpoint inhibitors have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, Hodgkin ’s lymphoma, bladder cancer and gastric cancer. However...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Prabhu VV, Devaraj N Abstract Lung cancer is responsible for 1.6 million deaths. Approximately 80%-85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach-surgery, chemotherapy, radiotherapy, and/or immunotherapy-is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-spe...
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Conclusion: Nivolumab demonstrated clinically meaningful activity and satisfactory safety profile as 2nd line treatment for patients with advanced NSCLC.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Conclusion: The use of nivolumab in routine NSCLC treatment shows promising efficacy consistent to the results of randomised clicinal trials. Despite a similar spectrum of irAE, therapy-related deaths occurred in our cohort. Thus, good selection and close monitoring is just as essential in routine care patients.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
by Violaine Yvorel, Arnaud Patoir, Fran çois Casteillo, Claire Tissot, Pierre Fournel, Marie-Laure Stachowicz, Georgia Karpathiou, Olivier Tiffet, Michel Péoc’h, Fabien Forest Lung sarcomatoid carcinoma of the lung is a rare tumor with a poor prognosis. More than 90% of them are pleomorphic, spindle cell and giant cell carcinoma (PSCGCC). This rare subtype of lung cancer is thought to be more resistant to chemotherapy, and a small subset of them seems to exhibit targeta ble mutations. Immunotherapy against PD1/PDL-1 is a new emerging treatment, and might be of interest in PSGSCC because they frequently...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
SECOND-LINE THERAPY OF SQUAMOUS NON-SMALL CELL LUNG CANCER: AN EVOLVING LANDSCAPE. Expert Rev Respir Med. 2017 May 03;: Authors: Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M Abstract INTRODUCTION: The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case of lung squamous cell carcinoma (LSCC...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news
This article is protected by copyright. All rights reserved. PMID: 27291635 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Lung cancer is diagnosed in nearly 225,000 patients each year in the United States. Majority of the patients present with advanced stage of the disease at the time of diagnosis. This is a major impediment to improving cure rates for patients with lung cancer. Lung cancer incidence rate is higher in African American (AA) patients compared to Caucasian patients. In addition, AA patients have certain important differences from Caucasian patients with lung cancer. They are more likely to be diagnosed at a younger age with lung cancer and also have a higher prevalence of smoking-related lung cancer. AA patients are more likely ...
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Lung Cancer: Oral Presentations - Invited Abstracts Source Type: research
Abstract Immunotherapy targeting the PD-L1/PD-1 axis has recently shown spectacular efficacy and promise for the future of patients with metastatic lung cancer. In the setting of second-line treatment of metastatic disease, this therapy has increased overall survival of patients by several months when compared to chemotherapy, both for squamous cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung. Clinical trials targeting the PD-1/PD-L1 axis have shown a tendency towards higher efficacy if expression of PD-L1 is relatively high, as evaluated by immunohistochemistry (IHC) of tumour samples. Targeting the PD-1...
Source: Virchows Archiv - Category: Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Merck | Squamous Cell Carcinoma